Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 2/2008

01-06-2008 | Case Report

Post-transplant lymphoproliferative disorder (PTLD) presenting as painful lymphocele 12 years after a cadaveric renal transplant

Authors: Mohammad S. Khan, Sami Ahmed, Ben Challacombe, David Goldsmith, Michael Steward

Published in: International Urology and Nephrology | Issue 2/2008

Login to get access

Abstract

We report a case of post-transplantation lymphoproliferative disorder presenting as a symptomatic lymphocele 12 years after cadaveric renal transplantation for IgA nephropathy. The presentation, imaging, and management are discussed. We review current literature concerning PTLD, post-transplantation lymphoceles, and state-of-the-art imaging techniques.
Literature
1.
Li PK, Tsang K, Szeto CC et al (1998) Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy. Am J Kidney Dis 32(5):813–819PubMedCrossRef
2.
Kew CE, Lopez-Ben R, Smith JK et al (2000) Post-transplant lymphoprolierative disorder localized near the allograft in renal transplants. Transplantation 69(5):809–814PubMedCrossRef
3.
Pickhardt PJ, Siegel MJ (1999) Post-transplant lymphoproliferative disorders of the abdomen. CT evaluation in 51 patients. Radiology 213(1):73–78PubMed
4.
Ali MG, Croakley FV, Hricak H et al (1999) Complex post-transplantation abnormalities of renal allografts: evaluation with MR imaging. Radiology 213(1):95–100
5.
Gulley ML, Swinnen LJ, Plaisance KT Jr (2003) Tumor origin and CD20 expression in post-transplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 76(6):959–964PubMedCrossRef
6.
Mamzer-Bruneel MF, Lome C, Morelon E et al (2000) Durable remission after aggressive chemotherapy for very late post-kidney lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 18(21):3622–3632PubMed
7.
Birkeland SA, Hamilton-Dutoit S, Bendtzen K (2003) Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation. Transplantation 76(1):153–158PubMedCrossRef
8.
Hamza A, Fischer K, Koch E et al (2006) Diagnostics and therapy of lymphoceles after kidney transplantation. Transplant Proc 38(3):701–706PubMedCrossRef
9.
Smyth GP, Beitz G, Eng MP et al (2006) Long-term outcome of cadaveric renal transplants after treatment of symptomatic lymphocele. J Urol 176(3):1069–1072PubMedCrossRef
Metadata
Title
Post-transplant lymphoproliferative disorder (PTLD) presenting as painful lymphocele 12 years after a cadaveric renal transplant
Authors
Mohammad S. Khan
Sami Ahmed
Ben Challacombe
David Goldsmith
Michael Steward
Publication date
01-06-2008
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2008
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9367-2

Other articles of this Issue 2/2008

International Urology and Nephrology 2/2008 Go to the issue

Original Paper

Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation

Original Article

Supracostal access for percutaneous nephrolithotomy: less morbid, more effective

Original Article

Comparison of four different anesthesia methods for relief of all pain during transrectal ultrasound-guided prostate biopsy

Original Article

The influence of atherosclerosis and plasma D-dimer concentration in patients with a functioning arteriovenous fistula for maintenance hemodialysis

Original Article

Glomerulonephritis causing acute renal failure during the course of bacterial infections. Histological varieties, potential pathogenetic pathways and treatment

Original Article

Cyclooxygenase-2 expression: Does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits